Methodology of a new inflammatory arthritis registry: TReasure

Authors: UMUT KALYONCU, ETEM KORAY TAŞCILAR, ALİ İHSAN ERTENLİ, HÜSEYİN EDİZ DALKILIÇ, CEMAL BES, ORHAN KÜÇÜKŞAHİN, TİMUÇİN KAŞİFOĞLU, NİLÜFER ALPAY KANITEZ, HAKAN EMMUNGİL, GEZMİŞ KİMYON, NAZİFE ŞULE YAŞAR BİLGE, SERVET AKAR, MEHMET PAMİR ATAGÜNDÜZ, SÜLEYMAN SERDAR KOCA, AŞKIN ATEŞ, VELİ YAZISIZ, MUSTAFA ENDER TERZİOĞLU, EMİNE DUYGU ERSÖZLÜ, MÜGE AYDIN TUFAN, MUHAMMET ÇINAR, RIDVAN MERCAN, ALİ ŞAHİN, ŞÜKRAN ERTEN, YAVUZ PEHLİVAN, SEDAT YILMAZ, AYŞE BAHAR KELEŞOĞLU DİNÇER, ÖNAY GERÇİK, BELKIS NİHAN COŞKUN, BURCU YAĞIZ, SEMA KAYMAZ TAHRA, AYSUN AKSOY, ÖMER KARADAĞ, LEVENT KILIÇ, SEDAT KİRAZ

Abstract: Background/aim: The TReasure registry, created in 2017, is an observational multicenter cohort that includes inflammatory arthritis patients. This article reviews the methodology and objectives of the TReasure registry established to collect data from rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients. Methodology: Fifteen rheumatology centers in Turkey will contribute data to the TReasure database. The actual proprietor of the database is the Hacettepe Rheumatology Association (HRD) and Hacettepe Financial Enterprises. Pharmaceutical companies that operate in Turkey (in alphabetical or er), Abbvie, Amgen, BMS, Celltrion Healthcare, Novartis, Pfizer, Roche, and UCB, support the TReasure registry. TReasure is a web-based database to which users connect through a URL (https://www.trials-network.org/treasure) with their unique identifier and passwords provided for data entry and access. TReasure records demographic and clinical features, comorbidities, radiology and laboratory results, measures of disease activity, and treatment data. Discussion: TReasure will provide us with various types of data, such as a cross-sectional view of the current nationwide status of the patients currently receiving these treatments, and retrospective data as much as allowed by the participating centers' records. Finally, a high-quality prospective dataset will be built over the ensuing years from patients with a new diagnosis of RA or SpA.

Keywords: Rheumatoid arthritis, spondyloarthritis, disease-modifying antirheumatic drugs, registry, TReasure

Full Text: PDF